|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.07.25 - 13:03
|
IQVIA Reports Second-Quarter 2025 Results (Business Wire)
|
|
|
Revenue of $4,017 million, up 5.3 percent year-over-year
GAAP Net Income of $266 million, Adjusted EBITDA of $910 million
GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81
R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x
R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year
TAS Revenue of $1,628 million, up 8.9 percent year-over-year
Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2025.
Second-Quarter 2025 Operating Results
Revenue for the second quarter of $4,017 million increased 5.3 percent on a reported basis and 3.6 percent at constant currency, compare...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
